Gilead Sciences (GILD) Change in Account Payables (2009 - 2026)

Gilead Sciences has reported Change in Account Payables for 18 years, with the latest figure at -$67.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 36.19% year-over-year to -$67.0 million; the trailing twelve-month figure through Mar 2026 stood at -$94.0 million (down 183.19% YoY), and the FY2025 full-year result was -$132.0 million, down 145.52% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$67.0 million, up from -$95.0 million in the prior quarter.
• The five-year high for Change in Account Payables was $359.0 million in Q3 2024, with the low at -$272.0 million in Q1 2023.
• Historically, Change in Account Payables has averaged -$1.8 million across 5 years, with a median of -$43.0 million in 2023.
• The largest YoY upside for Change in Account Payables was 1337.93% in 2024 against a maximum downside of 2666.67% in 2024.
• Gilead Sciences' Change in Account Payables stood at $264.0 million in 2022, then sank by 116.29% to -$43.0 million in 2023, then tumbled by 34.88% to -$58.0 million in 2024, then plunged by 63.79% to -$95.0 million in 2025, then climbed by 29.47% to -$67.0 million in 2026.
• The last three Change in Account Payables figures came in at -$67.0 million (Q1 2026), -$95.0 million (Q4 2025), and $230.0 million (Q3 2025), per Business Quant data.